Recruiting

Observational Study

Sponsor:

Washington University School of Medicine

Code:

NCT03141021

Conditions

Malignant Peripheral Nerve Sheath Tumors

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

First, the investigators plan to use a retrospective analysis to determine the clinical landscape of neurofibromatosis (NF)1-associated malignant peripheral nerve sheath tumor (MPNST) and precursor lesions (e.g., atypical or nodular plexiform neurofibromas). A worldwide database will be established, collecting, in a standardized manner, histologic, immunohistochemical, molecular, radiographic, treatment, and related clinical data from centers worldwide with expertise in these NF1-related cancers. Although retrospective in nature, the resulting data from this registry may reveal previously unanticipated patterns, similar to the INFACT effort outcome. This registry would then allow the acquisition of data associated with MPNST biospecimens collected under associated banks (frozen or paraffin-embedded, germline (or normal tissue DNA) samples, and any previously somatic whole-exome or whole-genome sequencing data for aggregate analyses). Second, the investigators plan to co-register patients to institutional banks in order to prospectively collect MPNST samples for analysis. These patients will be consented in order to collect the above information and for banking of tumor tissue and future studies that include genomic characterization of the tumors.

Conditions

Malignant Peripheral Nerve Sheath Tumors

Study ID

NCT03141021

Start date

Apr 28, 2017

Status verified date

Mar, 2026

Completion date

Apr 30, 2053

Anticipated

Primary completion date

Apr 30, 2053

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Inclusion Criteria and Exclusion Criteria:

-Any patient diagnosed with an MPNST is eligible for enrollment to this registry provided s/he consents to participate (or consent form his/her parent or legal guardian or legally authorized representative is obtained).

Study Design

Enrollment

1050 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Histologic characteristics of malignant peripheral nerve sheath tumor (MPNST) [ Time Frame: 10 years ]
  • Immunohistochemical characteristics of malignant peripheral nerve sheath tumor (MPNST) [ Time Frame: 10 years ]
  • Molecular characteristics of malignant peripheral nerve sheath tumor (MPNST) [ Time Frame: 10 years ]
  • Radiographic characteristics of malignant peripheral nerve sheath tumor (MPNST) [ Time Frame: 10 years ]
  • Treatment given to patients with malignant peripheral nerve sheath tumor (MPNST) [ Time Frame: 10 years ]
  • Future genomic characterization of malignant peripheral nerve sheath tumor (MPNST) [ Time Frame: 10 years ]

Central Contacts and Locations

Central contacts

Angela Hirbe, M.D., Ph.D.

(314) 362-8965hirbea@wustl.edu

Locations

Johns Hopkins

Recruiting

Baltimore, Maryland, United States, 21205

Contacts

Christine Pratilas, M.D.

410-955-8751

Principal Investigator:

Christine Pratilas, M.D.

Washington University School of Medicine

Recruiting

St Louis, Missouri, United States, 63110

Contacts

Angela Hirbe, M.D., Ph.D.

(314) 362-8965hirbea@wustl.edu

Principal Investigator:

Angela Hirbe, M.D., Ph.D.

Mount Sinai

Recruiting

Toronto, Ontario, Canada, M5T 3L9

Contacts

Principal Investigator:

Jay Wunder, M.D.

More Information

Sponsor

Washington University School of Medicine

Last update posted

Mar 9, 2026

Last verified

Mar, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Washington University School of Medicine on 2026-03-09.